Curaleaf Holdings (CURLF) Operating Margin (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Operating Margin of 0.23% for Q1 2026, down 282.0% year-on-year from 0.13% in Q1 2025, and down 92.71% on a QoQ basis from 3.19% in Q4 2025.
Curaleaf Holdings (CURLF) Operating Margin (2019 - 2026) Analysis & Trends
Curaleaf Holdings (CURLF) has reported Operating Margin for 8 consecutive years, with 0.23% the latest figure, recorded in Q1 2026.
- Quarterly Operating Margin fell 282.0% year-over-year to 0.23% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 1.43% (down 21.0% YoY) and the FY2025 annual result came in at 2.01%, up 15.0% from the prior year.
- Operating Margin retreated to 0.23% in Q1 2026 per CURLF's latest filing, from 3.19% in the prior quarter.
- Over the last five years, Operating Margin for CURLF reached as high as 14.02% in Q1 2022 and fell as low as 23.21% in Q4 2022.
- A 5-year average of 2.16% and a median of 2.79% in 2024 frame the typical range for Operating Margin.
- Annual changes were most pronounced in 2022 — Operating Margin sank 2661 bps — and 2023, when it jumped 2725 bps.
- Year by year, Operating Margin stood at 23.21% in 2022, then surged by 117 bps to 4.05% in 2023, then tumbled by 136 bps to 1.47% in 2024, then surged by 317 bps to 3.19% in 2025, then plunged by 93 bps to 0.23% in 2026.
- According to Business Quant data, Operating Margin over the past three periods registered 0.23%, 3.19%, and 1.26% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Curaleaf Holdings | 7.13 Bn | 7.13 Bn | 157.29 Mn | 0.23% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.23% |
| Dec 31, 2025 | 3.19% |
| Sep 30, 2025 | 1.26% |
| Jun 30, 2025 | 1.04% |
| Mar 31, 2025 | 3.05% |
| Dec 31, 2024 | -1.47% |
| Sep 30, 2024 | 2.79% |
| Jun 30, 2024 | 2.20% |
| Mar 31, 2024 | 0.00% |
| Dec 31, 2023 | 4.05% |
| Sep 30, 2023 | 4.57% |
| Jun 30, 2023 | -1.27% |
| Mar 31, 2023 | 5.40% |
| Dec 31, 2022 | -23.21% |
| Sep 30, 2022 | 10.02% |
| Jun 30, 2022 | 10.77% |
| Mar 31, 2022 | 14.02% |
| Dec 31, 2021 | 3.41% |
| Sep 30, 2021 | 13.20% |
| Jun 30, 2021 | 17.18% |